Elisabeth Hofmeister, M.Sc.
Doktorandin und wissenschaftliche Mitarbeiterin
Innovation and Entrepreneurship Research
+49 89 24246-579
elisabeth.hofmeister(at)ip.mpg.de
Arbeitsbereiche:
Innovationsökonomik, Gesundheitsökonomik, Industrieökonomik, Wettbewerbsökonomik
Wissenschaftlicher Werdegang
Seit 04/2022
Postgraduales Studium Betriebswirtschaftliche Forschung (MBR), Ludwig-Maximilians-Universität (LMU) München
Seit 10/2021
Wissenschaftliche Mitarbeiterin und Doktorandin am Max-Planck-Institut für Innovation und Wettbewerb (Innovation and Entrepreneurship Research)
09/2018 – 09/2021
Master of Science (M.Sc.) in Management & Technology mit Major in Chemie, Technische Universität München (TUM)
08/2016 – 12/2016
Auslandssemester an der University of Hong Kong
09/2014 – 09/2018
Bachelor of Science (B.Sc.) in Management & Technology mit Minor in Chemie, Technische Universität München (TUM)
Beruflicher Werdegang
06/2020 – 09/2021
Werkstudentin Consulting Services, IQVIA Commercial GmbH & Co. OHG, München
09/2019 – 12/2019
Praktikum Business Development, Fresenius Kabi Asia Pacific Ltd., Hong Kong
04/2019 – 09/2019
Projektstudium „Forum der Zukunft”, Deutsches Museum, München
09/2018 – 07/2019
Werkstudentin Business Development, InGeneron GmbH, München
04/2018 – 07/2018
Praktikum CFO Office / Global Business Services, Fresenius Kabi Deutschland GmbH, Bad Homburg
10/2017 – 03/2018
Praktikum Audit Corporate, KPMG AG Wirtschaftsprüfungsgesellschaft, München
03/2017 – 05/2017
Projektstudium „Internationalität in Human Resources“, MAN Truck & Bus AG, München
08/2015 – 06/2016
Werkstudentin Consulting, ROI Management Consulting AG, München
Stipendien
Seit 10/2018
TUM Finance and Accounting Selected Talents (TUMfast)
Publikationen
Diskussionspapiere
(2022). CRISPR/Cas Technology and Innovation: Mapping Patent Law Issues, Max Planck Institute for Innovation & Competition Research Paper, No. 22-06.
- The paper provides a systematic overview of issues arising at the interface between CRISPR/Cas technology and patent law. In particular, it examines aspects related to the patentability of CRISPR/Cas-based methods of genome editing, on the one hand, and access to patented technologies, in view of the expanding CRISPR patent landscape, on the other hand. On the whole, our findings show that the case of CRISPR/Cas technology is prototypical of the policy dilemma in patent law as to how to balance economic incentives of multiple innovators in a cumulative innovation setting. The reviewed technical, legal and economic factors suggest the preconditions for technology underutilisation. While this paper presents the results of the exploratory phase of research, it sets a framework for the further, more targeted interdisciplinary examination of the identified issues.
- Available at SSRN